Plus Therapeutics announced on March 4, 2025, the pricing of a private placement expected to generate approximately $15.0 million in gross proceeds. This financing is intended to strengthen the company's ability to rapidly advance its CNS cancer therapies.
The offering consisted of 28,042,140 common units or pre-funded units, each including common stock or a pre-funded warrant, and Series A and Series B warrants. The offering price per common unit was $0.66.
Approximately $5.31 million of the proceeds were generated from the cancellation of previously issued outstanding senior convertible promissory notes. The funds were placed in escrow, contingent on Nasdaq confirming the company would not be delisted by March 31, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.